Wednesday, January 3, 2024

We are pleased to inform you that by Provision DI-2023-6029-APN-ANMAT#MS of August 7, 2023

The National Administration of Drugs, Food and Medical Technology has renewed the Authorization of FP Clinical Pharma S.R.L. to carry out PHASE IV CLINICAL PHARMACOLOGY STUDIES OF BIOEQUIVALENCE IN ADULT POPULATION.

The National Administration of Drugs, Food and Medical Technology has renewed the Authorization of FP Clinical Pharma S.R.L. to carry out PHASE IV CLINICAL PHARMACOLOGY STUDIES OF BIOEQUIVALENCE IN ADULT POPULATION.

We are ready to face your next Bioequivalence project!!!!

View file

Related news

Wednesday, January 3, 2024

We congratulate Laboratorio BETA for the declaration of #BIOEQUIVALENCE of the product DROPICINE®/RISPERIDONE, 1mg coated tablets.

Read more
Wednesday, January 3, 2024

We are pleased to inform you that by Provision DI-2023-6029-APN-ANMAT#MS of August 7, 2023

Read more